ATE129900T1 - Anwendung von il-4 zur steigerung der immunantwort auf immunogene in impfstoffen. - Google Patents

Anwendung von il-4 zur steigerung der immunantwort auf immunogene in impfstoffen.

Info

Publication number
ATE129900T1
ATE129900T1 AT92903012T AT92903012T ATE129900T1 AT E129900 T1 ATE129900 T1 AT E129900T1 AT 92903012 T AT92903012 T AT 92903012T AT 92903012 T AT92903012 T AT 92903012T AT E129900 T1 ATE129900 T1 AT E129900T1
Authority
AT
Austria
Prior art keywords
immune response
immunogenes
vaccines
boost
application
Prior art date
Application number
AT92903012T
Other languages
English (en)
Inventor
Edward J Rozhon
John F O'connell
Stuart A Cox
Michael D Hayre
Jerome Schwartz
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE129900T1 publication Critical patent/ATE129900T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT92903012T 1990-12-19 1991-12-17 Anwendung von il-4 zur steigerung der immunantwort auf immunogene in impfstoffen. ATE129900T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62980090A 1990-12-19 1990-12-19

Publications (1)

Publication Number Publication Date
ATE129900T1 true ATE129900T1 (de) 1995-11-15

Family

ID=24524543

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92903012T ATE129900T1 (de) 1990-12-19 1991-12-17 Anwendung von il-4 zur steigerung der immunantwort auf immunogene in impfstoffen.

Country Status (20)

Country Link
EP (1) EP0563254B1 (de)
JP (1) JPH06503830A (de)
CN (1) CN1063227A (de)
AT (1) ATE129900T1 (de)
AU (1) AU9161591A (de)
CA (1) CA2098726A1 (de)
CZ (1) CZ119993A3 (de)
DE (1) DE69114519T2 (de)
DK (1) DK0563254T3 (de)
ES (1) ES2079851T3 (de)
FI (1) FI932759L (de)
GR (1) GR3018820T3 (de)
HU (1) HUT68529A (de)
IE (1) IE70453B1 (de)
IL (1) IL100402A0 (de)
OA (1) OA09863A (de)
PT (1) PT99838A (de)
SK (1) SK59393A3 (de)
WO (1) WO1992011030A1 (de)
ZA (1) ZA919907B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268454A (en) 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
US5206345A (en) * 1990-08-02 1993-04-27 Fred Hutchinson Cancer Research Center Il-4 and tnf induce mab 6g10-recognized expression on bone marrow stromal cells
US5827670A (en) * 1990-08-02 1998-10-27 Fred Hutchinson Cancer Research Center Methods of isolating and detecting bone marrow stromal cells with VCAM-1-specific antibodies
US7449186B1 (en) * 1990-08-02 2008-11-11 Fred Hutchinson Cancer Research Center Methods of blocking the interaction between stromal cells and hemopoietic cells with anti-VCAM-1 antibodies
AU688736B2 (en) * 1992-08-10 1998-03-19 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Interleukin-4 stimulated T lymphocyte cell death
WO1994028871A1 (en) * 1993-06-07 1994-12-22 Endocon, Inc. Implant stimulated cellular immunity
EP0752879A4 (de) * 1994-04-08 1999-07-21 Brigham & Womens Hospital Behandlung von autoimmun-krankheiten mittels oraler tolerierung und/oder th2-erhöhenden cytokinen
US6660258B1 (en) 1997-05-09 2003-12-09 Pharma Pacific Pty Ltd Oromucosal cytokine compositions and uses thereof
FR2769505B1 (fr) * 1997-10-10 2000-06-30 Michael Gerard Tovey Compositions de cytokines a administrer a la muqueuse buccale, et leurs utilisations
RU2138288C1 (ru) * 1998-06-03 1999-09-27 Акционерное общество открытого типа "Биомед" им.И.И.Мечникова Способ получения полимерной фракции столбнячного анатоксина
GB201821207D0 (en) 2018-12-24 2019-02-06 Tcer Ab Immunotherapy therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT83761B (pt) * 1985-11-19 1989-06-30 Schering Biotech Corp Metodo para a producao de interleuquina-4 de mamifero
NZ221298A (en) * 1986-08-01 1990-07-26 Commw Scient Ind Res Org A recombinant vaccine comprising an antigenic polypeptide component together with a lymphokine component
AU648509B2 (en) * 1989-07-14 1994-04-28 Wyeth Holdings Corporation Stable vaccine compositions containing interleukins
AU656889B2 (en) * 1990-03-21 1995-02-23 Schering Corporation Use of IL-4 to enhance immune response to infectious antigenic challenges

Also Published As

Publication number Publication date
DK0563254T3 (da) 1996-02-12
DE69114519D1 (de) 1995-12-14
SK59393A3 (en) 1994-03-09
WO1992011030A1 (en) 1992-07-09
FI932759A7 (fi) 1993-06-16
CN1063227A (zh) 1992-08-05
DE69114519T2 (de) 1996-04-04
JPH06503830A (ja) 1994-04-28
IL100402A0 (en) 1992-09-06
EP0563254B1 (de) 1995-11-08
FI932759A0 (fi) 1993-06-16
CA2098726A1 (en) 1992-06-20
HU9301797D0 (en) 1993-10-28
IE70453B1 (en) 1996-11-27
GR3018820T3 (en) 1996-04-30
CZ119993A3 (en) 1994-02-16
PT99838A (pt) 1992-12-31
IE914436A1 (en) 1992-07-01
HUT68529A (en) 1995-06-28
ES2079851T3 (es) 1996-01-16
AU9161591A (en) 1992-07-22
OA09863A (en) 1994-08-15
FI932759L (fi) 1993-06-16
EP0563254A1 (de) 1993-10-06
ZA919907B (en) 1992-08-26

Similar Documents

Publication Publication Date Title
MX9304089A (es) Uso de gm-csf como una vacuna adyuvante.
NO883896L (no) Fremgangsmaate til fremstilling av konjugater av cytokinermed menneskelig immunglobulin.
AU4951196A (en) Vaccines for plague
UA40597C2 (uk) Вакцинна композиція,спосіб лікування ссавців, що страждають або сприйнятливі до інфекції, спосіб лікування ссавців, що страждають на рак, спосіб одержання вакцинної композиції, композиція ад'ювантів
ATE129900T1 (de) Anwendung von il-4 zur steigerung der immunantwort auf immunogene in impfstoffen.
ATE125568T1 (de) Analoge der untereinheit des von rekombinanter dns abgeleiteten bordetella-toxins.
ATE103297T1 (de) Peptid, immunogene zusammensetzung und impfstoff oder medizinische zubereitung, eine methode zur immunisierung eines saeugetieres gegen lhrh und methode zur verbesserung von mea.
DE69122364D1 (de) Verwendung von (S)-Isofluran und (S)-Desfluran zur Anästhesie sowie entsprechende Arzneimittelzubereitungen
ATE268384T1 (de) Analog von haemophilus hin47 mit verminderter protease aktivität
PT1015595E (pt) Peptidos derivados da proteina de ligacao (g) do virus sincicial respiratorio
FR2746110B1 (fr) Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants
DE69031351D1 (de) Zubereitungen und behandlungen von pneumonia in tieren
DE69633233D1 (de) Multivalenter impstoff gegen bovines coronavirus und methode zur behandlung einer infektion mit bovinem coronavirus
ATE133074T1 (de) Verwendung von il-4 zur verstärkung der immunantwort auf infektiöse antigen- herausforderungen
ATE229981T1 (de) Glykolisierte cytokine
DE68917138D1 (de) Toleranzinduktion gegenüber einem fremdantigen.
NO892015D0 (no) Fremgangsmaate for fremstilling av et legemiddel.
ES2160927T3 (es) Composiciones farmaceuticas que comprenden interferon alfa humano natural.
ATE83381T1 (de) Verwendung von rekombiniertem menschlichem alpha- interferon zur herstellung eines arzneimittels zur behandlung des aids-virus.
ATE95422T1 (de) Ein synthetisches nonapeptid zur verwendung als adjuvant.
RU93043610A (ru) Фармацевтическая композиция для усиления первичной иммуно-реакции у млекопитающих, способ усиления первичной иммуно-реакции и применение интерлейкина-4 для усиления первичной иммуно-реакции у млекопитающих, набор лекарственных средств

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee